BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases » Page 51

L7 Informatics Releases L7 Enterprise Science Platform 2.0 with Pre-Built Microsoft Genomics Integration

By Leave a Comment

L7 ESP v.2.0 expands platform functionality to support complex “bench-to-bedside” life science industry and regulatory requirements

AUSTIN, Texas, Oct. 10, 2018 — L7 Informatics, Inc., formerly Lab7 Systems, a leader in informatics solutions and services for data intensive scientific applications and personalized medicine, is pleased to announce today the release of Enterprise Science Platform 2.0 (ESP) with a validated pre-built Microsoft Azure connector to the Microsoft Genomics service on the Azure cloud. [Read more…]

UniCAR Therapy and Terumo BCT Collaborate to Advance CAR T-Cell Therapies and Create a Shanghai, China Center of Excellence

By Leave a Comment

LAKEWOOD, Colo., Oct. 09, 2018 — Shanghai UniCAR-Therapy Bio-Medicine Technology Co. chose Terumo BCT and its cell expansion devices to automate its cell therapy manufacturing process for chimeric antigen receptor (CAR) T-cell therapies. Privately held, UniCAR will open their Center of Excellence for Terumo BCT’s technologies in Shanghai in November.

Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular therapy technologies. The company provides flexible solutions for CAR T-cell developers and manufacturers, including the Quantum® Cell Expansion System, in use at UniCAR today. [Read more…]

Gradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating their Phase 3 Study of Vigil™ in Ewing’s sarcoma

By Leave a Comment

Gradalis deploys L7’s Enterprise Science Platform for next-generation life science companies in record time to support mission-critical immunotherapy manufacturing and clinical trial processes.

DALLAS, October 3, 2018 – Gradalis, Inc., a Dallas-based, clinical-stage, vertically-integrated immunotherapy company, announced today it has successfully implemented and launched L7’s Enterprise Science Platform (“ESP”). L7 Informatics, Inc., is the leading software and analytics company for life science research and manufacturing companies.

Gradalis recently upgraded its Carrollton, TX manufacturing facility to support the launch of a Phase 3 registration trial of Vigil in Ewing’s sarcoma. Gradalis’ vertically integrated research, clinical and manufacturing business model creates complex master batch record (“MBR”) requirements that few technology providers can support. [Read more…]

BioStem Life Sciences, Inc., Subsidiary of BioStem Technologies, Inc., Announces Entry into Market with Four Amniotic Products

By Leave a Comment

Pompano Beach, FL, Oct. 01, 2018 — BioStem Life Sciences (“Life Sciences” or the “Company”), a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM), a Company focused on the development of the highest quality placental-based amniotic tissue products, whose mission is to create a new paradigm of healthcare, using breakthrough therapies that treat patients who otherwise are without effective treatment options, announced today that it has entered the market with four placental-derived tissue products for multiple indications within the ophthalmology, orthopedic and advanced wound care markets. [Read more…]

Exosome Start-up ExoCoBio Inc. raises $26.7M in Series B Funding

By Leave a Comment

  • ExoCoBio is the 4th largest funded exosome startup in the world

  • ExoCoBio is using the funding to advance its exosome pharmaceutical R&D and cosmeceutical business

SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment.
[Read more…]

BioInformant's World-Class Clients